Alx Oncology Holdings Inc (ALXO) Stock Price & Analysis
Alx Oncology Holdings Inc (ALXO) rose 0.50% to USD 2.03 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
ALXO last closed at USD 2.02; the session ranged USD 1.97–2.08 on volume of 995,491 shares. Market capitalization is $273.16M, with a 52-week range of USD 0.51–2.66 (NMS). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 2.03 |
|---|---|
| Change | ▲ 0.50% (up) |
| Previous Close | USD 2.02 |
| Open | USD 2.03 |
| Day Range | USD 1.97 – 2.08 |
| 52-Week Range | USD 0.51 – 2.66 |
| Volume | 995,491 shares |
| Market Cap | $273.16M |
| Exchange | NMS |
Technical Analysis (ALXO)
Nexqual's technical model rates ALXO "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.23 (neutral) |
| vs SMA50 | Above (USD 1.89) |
| MACD | 0.05 (positive) |
Analyst Ratings (ALXO)
Wall Street analysts rate ALXO "None" based on 5 analysts, with a mean price target of USD 4.6 (range USD 4–6), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.6 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (ALXO)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.16 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.16 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.32 ▼ miss |
| 2025-09-30 | USD -0.41 vs est -0.37 ▼ miss |
| 2025-06-30 | USD -0.44 vs est -0.31 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (ALXO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.17% |
| Debt / Equity | 8.62 |
| Current Ratio | 7.21 |
| Total Cash | $140.32M |
| Total Debt | $13.05M |
| Free Cash Flow | $-47.77M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (ALXO)
Nexqual rates Alx Oncology Holdings Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $140M cash vs $13M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$78M |
| Efficiency | Critical — ROE -74%, ROA -36.8% |
Ownership (ALXO)
| Insider Ownership | +0.92% |
|---|---|
| Institutional Ownership | +78.82% |
| Shares Outstanding | 134.56M |
| Float | 77.44M |
| Short % of Float | +5.22% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Leadership (ALXO)
Alx Oncology Holdings Inc is led by Jason W. Lettmann (age 48), CEO & Director, per Nexqual as of July 25, 2026 at 03:03 UTC.
| CEO & Director | Jason W. Lettmann (age 48) |
|---|---|
| Chief Financial Officer | Harish Shantharam C.F.A. (age 44) |
| Senior Vice President of Clinical Development | Athanasios Tsiatis |
| Senior Vice President of Drug Safety & Pharmacovigilance | Lin Yeong-Liang M.D., M.S. |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Lisa Sauer |
Major Backers & Investors (ALXO)
Notable institutional backers of Alx Oncology Holdings Inc include RA Capital Management, L.P., TCG Crossover Management, LLC, venBio Partners LLC, according to Nexqual as of July 25, 2026 at 03:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.67% |
| TCG Crossover Management, LLC | 9.67% |
| venBio Partners LLC | 9.58% |
| Redmile Group, LLC | 5.92% |
| Blackstone Inc | 4.33% |
| Driehaus Capital Management, LLC | 4.26% |
| Marshall Wace LLP | 2.79% |
| Vivo Capital, LLC | 2.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.29% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
From Alx Oncology Holdings Inc's Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
- The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
- It has license agreements with Board of Trustees of Leland Stanford Junior University.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NKTX | Nkarta, Inc. | USD 2.27 | ▼ 5.81% |
| ANNX | Annexon, Inc. | USD 5.22 | ▼ 0.19% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.24 | ▼ 6.77% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.